Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(8):679–685. doi: 10.1111/j.1349-7006.2003.tb01502.x

Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice

Takanobu Kato 1, Michiko Miyamoto 1, Tomoko Date 1, Kotaro Yasui 1, Choji Taya 2, Hiromichi Yonekawa 2, Chiharu Ohue 3, Shintaro Yagi 3, Ekihiro Seki 4, Tadamichi Hirano 4, Jiro Fujimoto 4, Tomoyuki Shirai 5, Takaji Wakita 1,✉
PMCID: PMC11160254  PMID: 12901792

Abstract

Although hepatitis C virus (HCV) is a well‐known causative agent of hepatocellular carcinoma (HCC), the mechanism by which HCV induces HCC remains obscure. To elucidate the role of HCV in hepatocarcinogenesis, a model of hepatocyte injury was established using HCV core transgenic mice, which were developed using C57BL/6 mice transfected with the HCV core gene under control of the serum amyloid P component promoter. After 18–24 months, neither steatosis nor hepatic tumors were found in transgenic mice. The extent of hepatocyte injury and tumorigenesis were then examined in transgenic mice following repeated administration of carbon tetrachloride (CCl4) using various protocols (20%, 1/week; 10%, 2/week and 20%, 2/week). Serum alanine aminotransferase (ALT) levels did not differ among HCV core transgenic mice and non‐transgenic littermates; however, after 40 weeks, hepatic adenomas preferentially developed in transgenic mice receiving 20% CCl4 once weekly. Moreover, HCC was observed in transgenic mice receiving 2 weekly injections of a 20% solution of CCl4, and was not observed in the non‐transgenic control mice. In conclusion, the HCV core protein did not promote hepatic steatosis or tumor development in the absence of hepatotoxicity. However, the HCV core protein promoted adenoma and HCC development in transgenic mice following repeated CCl4 administration. These results suggest that hepatotoxicity resulting in an increased rate of hepatocyte regeneration enhances hepatocarcinogenesis in HCV‐infected livers. Furthermore, this experimental mouse model provides a valuable method with which to investigate hepatocarcinogenesis.

References

  • 1. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH. Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671–5. [DOI] [PubMed] [Google Scholar]
  • 2. Tong MJ, El‐Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion‐associated hepatitis C. N Engl J Med 1995; 332: 1463–6. [DOI] [PubMed] [Google Scholar]
  • 3. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–9. [DOI] [PubMed] [Google Scholar]
  • 4. Sharan R, Schoen RE. Cancer in inflammatory bowel disease. An evidence‐based analysis and guide for physicians and patients. Gastroenterol Clin North Am 2002; 31: 237–54. [DOI] [PubMed] [Google Scholar]
  • 5. Burroughs AK, Bassendine MF, Thomas HC, Sherlock S. Primary liver cell cancer in autoimmune chronic liver disease. Br Med J ( Clin Res Ed ) 1981; 282: 273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Ryder SD, Koskinas J, Rizzi PM, McFarlane IG, Portmann BC, Naoumov NV, Williams R. Hepatocellular carcinoma complicating autoimmune hepatitis: role of hepatitis C virus. Hepatology 1995; 22: 718–22. [PubMed] [Google Scholar]
  • 7. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood‐borne non‐A, non‐B viral hepatitis genome. Science 1989; 244: 359–62. [DOI] [PubMed] [Google Scholar]
  • 8. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo M, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW, Houghton M. An assay for circulating antibodies to a major etiologic virus of human non‐A, non‐B hepatitis. Science 1989; 244: 362–4. [DOI] [PubMed] [Google Scholar]
  • 9. Ray RB, Lagging LM, Meyer K, Steele R, Ray R. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995; 37: 209–20. [DOI] [PubMed] [Google Scholar]
  • 10. Ray RB, Lagging LM, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 1996; 70: 4438–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Honda M, Kaneko S, Shimazaki T, Matsushita E, Kobayashi K, Ping LH, Zhang HC, Lemon SM. Hepatitis C virus core protein induces apoptosis and impairs cell‐cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology 2000; 31: 1351–9. [DOI] [PubMed] [Google Scholar]
  • 12. Kato N, Yoshida H, Kioko Ono‐Nita S, Kato J, Goto T, Otsuka M, Lan K, Matsushima K, Shiratori Y, Omata M. Activation of intracellular signaling by hepatitis B and C viruses: C‐viral core is the most potent signal inducer. Hepatology 2000; 32: 405–12. [DOI] [PubMed] [Google Scholar]
  • 13. Otsuka M, Kato N, Taniguchi H, Yoshida H, Goto T, Shiratori Y, Omata M. Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl‐xL expression. Virology 2002; 296: 84–93. [DOI] [PubMed] [Google Scholar]
  • 14. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065–7. [DOI] [PubMed] [Google Scholar]
  • 15. Zhao X, Araki K, Miyazaki J, Yamamura K. Developmental and liver‐specific expression directed by the serum amyloid P component promoter in transgenic mice. J Biochem ( Tokyo ) 1992; 111: 736–8. [DOI] [PubMed] [Google Scholar]
  • 16. Wakita T, Taya C, Katsume A, Kato J, Yonekawa H, Kanegae Y, Saito I, Hayashi Y, Koike M, Kohara M. Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system. J Biol Chem 1998; 273: 9001–6. [DOI] [PubMed] [Google Scholar]
  • 17. Wakita T, Katsume A, Kato J, Taya C, Yonekawa H, Kanegae Y, Saito I, Hayashi Y, Koike M, Miyamoto M, Hiasa Y, Kohara M. Possible role of cytotoxic T cells in acute liver injury in hepatitis C virus cDNA transgenic mice mediated by Cre/loxP system. J Med Virol 2000; 62: 308–17. [DOI] [PubMed] [Google Scholar]
  • 18. Moradpour D, Wakita T, Tokushige K, Carlson RI, Krawczynski K, Wands JR. Characterization of three novel monoclonal antibodies against hepatitis C virus core protein. J Med Virol 1996; 48: 234–41. [DOI] [PubMed] [Google Scholar]
  • 19. Aoyagi K, Ohue C, Iida K, Kimura T, Tanaka E, Kiyosawa K, Yagi S. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 1999; 37: 1802–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Kato T, Furusaka A, Miyamoto M, Date T, Yasui K, Hiramoto J, Nagayama K, Tanaka T, Wakita T. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J Med Virol 2001; 64: 334–9. [DOI] [PubMed] [Google Scholar]
  • 21. Tsuchihara K, Hijikata M, Fukuda K, Kuroki T, Yamamoto N, Shimotohno K. Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology 1999; 258: 100–7. [DOI] [PubMed] [Google Scholar]
  • 22. Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M, Yoshimura A. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 2002; 196: 641–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus‐associated hepatocarcinogenesis. Cancer Res 2001; 61: 4365–70. [PubMed] [Google Scholar]
  • 24. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366–75. [DOI] [PubMed] [Google Scholar]
  • 25. Tsutsumi T, Suzuki T, Shimoike T, Suzuki R, Moriya K, Shintani Y, Fujie H, Matsuura Y, Koike K, Miyamura T. Interaction of hepatitis C virus core protein with retinoid × receptor alpha modulates its transcriptional activity. Hepatology 2002; 35: 937–46. [DOI] [PubMed] [Google Scholar]
  • 26. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA, Lemon SM. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002; 122: 352–65. [DOI] [PubMed] [Google Scholar]
  • 27. Pasquinelli C, Shoenberger JM, Chung J, Chang KM, Guidotti LG, Selby M, Berger K, Lesniewski R, Houghton M, Chisari FV. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 1997; 25: 719–27. [DOI] [PubMed] [Google Scholar]
  • 28. Kawamura T, Furusaka A, Koziel MJ, Chung RT, Wang TC, Schmidt EV, Liang TJ. Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology 1997; 25: 1014–21. [DOI] [PubMed] [Google Scholar]
  • 29. Matsuda J, Suzuki M, Nozaki C, Shinya N, Tashiro K, Mizuno K, Uchinuno Y, Yamamura K. Transgenic mouse expressing a full‐length hepatitis C virus cDNA. Jpn J Cancer Res 1998; 89: 150–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Honda A, Arai Y, Hirota N, Sato T, Ikegaki J, Koizumi T, Hatano M, Kohara M, Moriyama T, Imawari M, Shimotohno K, Tokuhisa T. Hepatitis C virus structural proteins induce liver cell injury in transgenic mice. J Med Virol 1999; 59: 281–9. [DOI] [PubMed] [Google Scholar]
  • 31. Honda A, Hatano M, Kohara M, Arai Y, Hartatik T, Moriyama T, Imawari M, Koike K, Yokosuka O, Shimotohno K, Tokuhisa T. HCV‐core protein accelerates recovery from the insensitivity of liver cells to Fas‐mediated apoptosis induced by an injection of anti‐Fas antibody in mice. J Hepatol 2000; 33: 440–7. [DOI] [PubMed] [Google Scholar]
  • 32. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Brechot C. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94: 1200–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Sabile A, Perlemuter G, Bono F, Kohara K, Demaugre F, Kohara M, Matsuura Y, Miyamura T, Brechot C, Barba G. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 1999; 30: 1064–76. [DOI] [PubMed] [Google Scholar]
  • 34. Moradpour D, Englert C, Wakita T, Wands JR. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 1996; 222: 51–63. [DOI] [PubMed] [Google Scholar]
  • 35. Mourelle M, Villalon C, Amezcua JL. Protective effect of colchicine on acute liver damage induced by carbon tetrachloride. J Hepatol 1988; 6: 337–42. [DOI] [PubMed] [Google Scholar]
  • 36. Dragani TA, Manenti G, Della Porta G. Enhancing effects of carbon tetrachloride in mouse hepatocarcinogenesis. Cancer Lett 1986; 31: 171–9. [DOI] [PubMed] [Google Scholar]
  • 37. Williams AT, Burk RF. Carbon tetrachloride hepatotoxicity: an example of free radical‐mediated injury. Semin Liver Dis 1990; 10: 279–84. [DOI] [PubMed] [Google Scholar]
  • 38. Tsunematsu S, Saito H, Kagawa T, Morizane T, Hata J, Nakamura T, Ishii H, Tsuchiya M, Nomura T, Katsuki M. Hepatic tumors induced by carbon tetrachloride in transgenic mice carrying a human c‐H‐ras proto‐oncogene without mutations. Int J Cancer 1994; 59: 554–9. [DOI] [PubMed] [Google Scholar]
  • 39. Tarao K, Rino Y, Ohkawa S, Shimizu A, Tamai S, Miyakawa K, Aoki H, Imada T, Shindo K, Okamoto N, Totsuka S. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus‐associated cirrhosis. Cancer 1999; 86: 589–95. [DOI] [PubMed] [Google Scholar]
  • 40. Kasahara A, Hayashi N, Mochizuki K, Hiramatsu N, Sasaki Y, Kakumu S, Kiyosawa K, Okita K. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group. J Viral Hepat 2000; 7: 343–51. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES